Test your knowledge of GOLD 2026 updates and how early diagnosis and timely LAMA-based maintenance therapy can reduce exacerbations and preserve lung function in COPD.
6 questions
According to GOLD 2026, which symptom cluster should prompt diagnostic evaluation for COPD in at-risk patients?
Correct Answer: A
GOLD 2026 reaffirms that dyspnea, chronic cough, and sputum production remain hallmark symptoms of COPD, particularly in individuals with risk factors such as smoking or occupational exposure. Early recognition supports timely diagnosis and intervention.
https://www.tandfonline.com/doi/full/10.1080/17476348.2023.2171990
https://goldcopd.org/2026-gold-report-and-pocket-guide/
What does GOLD 2026 highlight when comparing long-acting muscarinic antagonist (LAMA) therapy with long-acting β₂-agonist (LABA) therapy for COPD exacerbation prevention?
Correct Answer: B
Comparative data summarized in GOLD 2026 indicate that LAMA therapy provides greater reduction in exacerbations and hospitalization risk than LABA monotherapy, with similar improvements in lung function.
Why is early diagnosis of COPD clinically significant?
Evidence suggests that lung function decline may be more rapid in earlier stages of COPD. Early diagnosis allows timely initiation of maintenance therapy to help preserve lung function and potentially alter disease trajectory.
https://link.springer.com/article/10.1007/s12325-023-02583-1
https://www.mdpi.com/2077-0383/14/2/397
What is the long-term impact of recurrent COPD exacerbations?
Correct Answer: C
Exacerbations are associated with accelerated and often permanent declines in lung function, increased risk of future exacerbations, and higher mortality. Preventing early exacerbations is central to long-term disease management.
What is the primary benefit of initiating long-acting bronchodilator therapy (e.g., LAMA or LAMA/LABA) early in the course of COPD?
Clinical evidence and predictive modelling suggest that early initiation of maintenance therapy with LAMA or LAMA/LABA reduces exacerbation frequency and preserves lung function over time compared with delayed treatment. These benefits may contribute to delayed disease progression.
Which spirometric measures does GOLD 2026 recommend for confirming persistent airflow limitation in COPD?
Correct Answer: D
GOLD 2026 continues to recommend post-bronchodilator FEV₁ and the FEV₁/FVC ratio as the most reliable and reproducible measures for confirming persistent airflow limitation in COPD.